123 related articles for article (PubMed ID: 12439851)
1. Lack of specificity of cell-surface protease targeting of a cytotoxic hyperfusogenic gibbon ape leukaemia virus envelope glycoprotein.
Kirkham LA; Bateman AR; Melcher AA; Vile RG; Fielding AK
J Gene Med; 2002; 4(6):592-600. PubMed ID: 12439851
[TBL] [Abstract][Full Text] [Related]
2. Targeting the cytotoxicity of fusogenic membrane glycoproteins in gliomas through protease-substrate interaction.
Johnson KJ; Peng KW; Allen C; Russell SJ; Galanis E
Gene Ther; 2003 May; 10(9):725-32. PubMed ID: 12704411
[TBL] [Abstract][Full Text] [Related]
3. Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas.
Allen C; McDonald C; Giannini C; Peng KW; Rosales G; Russell SJ; Galanis E
J Gene Med; 2004 Nov; 6(11):1216-27. PubMed ID: 15459967
[TBL] [Abstract][Full Text] [Related]
4. A hyperfusogenic gibbon ape leukemia envelope glycoprotein: targeting of a cytotoxic gene by ligand display.
Fielding AK; Chapel-Fernandes S; Chadwick MP; Bullough FJ; Cosset FL; Russell SJ
Hum Gene Ther; 2000 Apr; 11(6):817-26. PubMed ID: 10779159
[TBL] [Abstract][Full Text] [Related]
5. Gene therapy for malignant glioma using Sindbis vectors expressing a fusogenic membrane glycoprotein.
Zhang J; Frolov I; Russell SJ
J Gene Med; 2004 Oct; 6(10):1082-91. PubMed ID: 15368589
[TBL] [Abstract][Full Text] [Related]
6. Envelope fusion protein binding studies in an inducible model of retrovirus receptor expression and in CD34(+) cells emphasize limited transduction at low receptor levels.
Kurre P; Morris J; Miller AD; Kiem HP
Gene Ther; 2001 Apr; 8(8):593-9. PubMed ID: 11320405
[TBL] [Abstract][Full Text] [Related]
7. Fusion-defective gibbon ape leukemia virus vectors can be rescued by homologous but not heterologous soluble envelope proteins.
Farrell KB; Ting YT; Eiden MV
J Virol; 2002 May; 76(9):4267-74. PubMed ID: 11932392
[TBL] [Abstract][Full Text] [Related]
8. Targeting of retroviral vectors through protease-substrate interactions.
Nilson BH; Morling FJ; Cosset FL; Russell SJ
Gene Ther; 1996 Apr; 3(4):280-6. PubMed ID: 8732159
[TBL] [Abstract][Full Text] [Related]
9. A gene delivery system activatable by disease-associated matrix metalloproteinases.
Peng KW; Morling FJ; Cosset FL; Murphy G; Russell SJ
Hum Gene Ther; 1997 Apr; 8(6):729-38. PubMed ID: 9113512
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of retroviral vectors based on the gibbon ape leukemia virus.
Eglitis MA; Schneiderman RD; Rice PM; Eiden MV
Gene Ther; 1995 Sep; 2(7):486-92. PubMed ID: 7584127
[TBL] [Abstract][Full Text] [Related]
11. Selective transduction of protease-rich tumors by matrix-metalloproteinase-targeted retroviral vectors.
Peng KW; Vile R; Cosset FL; Russell S
Gene Ther; 1999 Sep; 6(9):1552-7. PubMed ID: 10490764
[TBL] [Abstract][Full Text] [Related]
12. Lentiviral vectors pseudotyped with envelope glycoproteins derived from gibbon ape leukemia virus and murine leukemia virus 10A1.
Stitz J; Buchholz CJ; Engelstädter M; Uckert W; Bloemer U; Schmitt I; Cichutek K
Virology; 2000 Jul; 273(1):16-20. PubMed ID: 10891403
[TBL] [Abstract][Full Text] [Related]
13. Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control.
Simpson GR; Han Z; Liu B; Wang Y; Campbell G; Coffin RS
Cancer Res; 2006 May; 66(9):4835-42. PubMed ID: 16651439
[TBL] [Abstract][Full Text] [Related]
14. Gibbon ape leukemia virus poorly replicates in primary human T lymphocytes: implications for safety testing of primary human T lymphocytes transduced with GALV-pseudotyped vectors.
Lamers CH; Willemsen RA; van Elzakker PM; Gratama JW; Debets R
J Immunother; 2009 Apr; 32(3):272-9. PubMed ID: 19242373
[TBL] [Abstract][Full Text] [Related]
15. Efficient transduction and engraftment of G-CSF-mobilized peripheral blood CD34+ cells in nonhuman primates using GALV-pseudotyped gammaretroviral vectors.
Beard BC; Mezquita P; Morris JC; Kiem HP
Mol Ther; 2006 Aug; 14(2):212-7. PubMed ID: 16631413
[TBL] [Abstract][Full Text] [Related]
16. Targeted retroviral vectors displaying a cleavage site-engineered hemagglutinin (HA) through HA-protease interactions.
Szécsi J; Drury R; Josserand V; Grange MP; Boson B; Hartl I; Schneider R; Buchholz CJ; Coll JL; Russell SJ; Cosset FL; Verhoeyen E
Mol Ther; 2006 Nov; 14(5):735-44. PubMed ID: 16784893
[TBL] [Abstract][Full Text] [Related]
17. Transduction of human hematopoietic progenitor cells with retroviral vectors based on the gibbon ape leukemia virus.
Eglitis MA; Schneiderman RD
Biochem Biophys Res Commun; 1997 Feb; 231(2):477-80. PubMed ID: 9070304
[TBL] [Abstract][Full Text] [Related]
18. Dissection of gammaretroviral receptor function by using type III phosphate transporters as models.
Farrell KB; Eiden MV
J Virol; 2005 Jul; 79(14):9332-6. PubMed ID: 15994829
[TBL] [Abstract][Full Text] [Related]
19. Library-based selection of retroviruses selectively spreading through matrix metalloprotease-positive cells.
Hartl I; Schneider RM; Sun Y; Medvedovska J; Chadwick MP; Russell SJ; Cichutek K; Buchholz CJ
Gene Ther; 2005 Jun; 12(11):918-26. PubMed ID: 15716977
[TBL] [Abstract][Full Text] [Related]
20. Masking of retroviral envelope functions by oligomerizing polypeptide adaptors.
Morling FJ; Peng KW; Cosset FL; Russell SJ
Virology; 1997 Jul; 234(1):51-61. PubMed ID: 9234946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
